Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the potential drug-drug interactions between dolutegravir (DTG) and
steady state rifapentine (RPT) when RPT is given with isoniazid (INH) daily for 4 weeks (1HP)
as part of treatment for latent TB infection (LTBI) in HIV-1 and LTBI co-infected
individuals.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
ViiV Healthcare ViiV Healthcare (VH)
Treatments:
Anti-Retroviral Agents Dolutegravir Isoniazid Pyridoxal Pyridoxine Rifampin Rifapentine Vitamin B 6 Vitamin B Complex Vitamins